Pathophysiology of pulmonary hypertension

Respiratory-Circulatory Interactions in Health and Disease

Volumn , Issue , 2001, Pages 447-478

  Yuan, Jason X J ^a   Rubin, Lewis J ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002329827     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (97)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117.
2. Abenheim L, Moride Y, Brenot F, Rich S, Benichou B, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335:509-516.
3. Wood P. Disease of the Heart and Circulation, 2nd ed. (Philadelphia: J.P. Lippincott, 1956.
4. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958; 20:557-570.
5. Wagenvoort CA. Vasoconstriction and medial hypertrophy in pulmonary hypertension. Circulation. 1960; 22:535-546.
6. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP. Primary pulmonary hypertension, Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989; 80:1207-1221.
7. Pietra GG. The pathology of primary pulmonary hypertension. In:Rubin LJ, Rich S, eds. Primary Pulmonary Hypertension. New York: Marcel Dekker, 1997:19-61.
8. Reid LM, Davies P. Control of cell proliferation in pulmonary hypertension. In:Weir EK, Reeves JT, eds. Pulmonary Vascular Physiology and Pathophysiology. New York: Marcel Dekker, 1989:541-641.
9. Stenmark KR, Mecham RP. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 1997; 59:89-144, 1997.
10. Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 1995; 146(2):389-397, 1995.
11. Davies PF, Tripathi SC. Mechanical stress mechanisms and the cell: an endothelial paradigm. Circ Res 1993; 72:239-245.
12. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-221.
13. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, Large LR, Wells FC, Wallwork J. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324:1539-1547.
14. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739.
15. Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E, Piette JC, Godeau P, Gandjbakhch I. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc. Res 1997; 33:196-200.
16. Fanburg BL, Lee S-L. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997; 272:L795-L806.
17. Voelkel NF, Hoeper M, Maloney J, Tuder RM. Vascular endothelial growth factor in pulmonary hypertension. Ann NY Acad Sci 1996; 796:186-193.
18. Golpe R, Fernandez-Infante B, Fernandez-Rozas S. Primary pulmonary hypertension associated with human imunodeficiency virus infection. Postgrad Med J 1998; 74:400-404.
19. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, Johnson LB. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999; 67(8):1087-1093.
20. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82(3):841-847.
21. Welsh Ch, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110(3):710-717.
22. Lopes AA, Maeda NY. Circulating von Willebrand factor antigen as a predictor of shortterm prognosis in pulmonary hypertension. Chest 1998; 114(5):1276-1282.
23. Geggel RL, Carvalho AC, Hoyer LW, Reid LM. Von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135(2):294-299.
24. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75.
25. Cacoub P, Dorent R, Carayon A. Thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:1456-1457.
26. Rich S, Kaufmann E, Levy PA. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81.
27. Rubin LJ, Nicod P, Hillis LD, Firth BG. Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med 1983; 99:433-438.
28. Lee SD, Shroyer SR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101(5):927-934.
29. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD Jr, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-301.
30. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F. Prostacyclin-induced pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66:334-338.
31. Kolpakov V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995; 76(2):305-309.
32. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109-121.
33. Hishikawa K, Nakaki T, Maruno T, Hayashi M, Suzuki H, Kato R, Saruta T. Pressure promotes DNA synthesis in rat cultured vascular smooth muscle cells. J Clin Invest 1994; 93:1975-1980.
34. Kolpakov V, Rekhtar MD, Gordon D, Wang WH, Kulik TJ. Effect of mechanical forces on growth and matrix protein synthesis in the in vitro pulmonary artery, analysis of the role of individual cell types. Circ Res 1995; 77:823-831.
35. Brink C, Cerrina C, Labat C, Veley J, Benveniste J. The effects of contractile agonists on isolated pulmonary arterial and venous muscle preparations derived from patients with primary pulmonary hypertension. Am Rev Respir Dis 1988; 137(part 2):A106.
36. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994; 372:231-236.
37. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361:315-325.
38. Berridge MJ. Calcium signaling and cell proliferation. BioEssays 1995; 17:491-500.
39. Clapham DE. Calcium signaling. Cell 1995; 80:259-268.
40. Means AR. Calcium calmodulin and cell cycle regulation. FEBS Lett 1994; 347:1-4.
41. Ginty DD. Calcium regulation of gene expression: isn’t that spatial? Cell 1997; 18:183-186.
42. Nelson MT, Patlak JB, Worley JF, Standen NB. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 1990; 259:C3-C18.
43. 2+ transients in guinea-pig coronary myocytes. J Physiol 1993; 470:35-44.
44. 2+ stores and cell responsiveness. Am J Physiol 1993; 264:C1367-1387.
45. 2+]i smooth muscle. Annu Rev Physiol 1989; 51:315-329.
46. Fleischmann BK, Murray RK, Kotlikoff MI. Voltage window for sustained elevation of cytosolic calcium in smooth muscle cells. Proc Natl Acad Sci USA 1994; 91:11914-11918.
47. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995; 268:C799-C822.
48. Yuan JX-J, Blaustein MP. Cellular potassium transport. In:Izzo JL Jr, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure, 2nd ed. Dallas: American Heart Association 1999:56-57.
49. 2+]i in pulmonary arterial myocytes. Circ Res 1995; 77:370-378.
50. + current that is active at resting potential in rabbit pulmonary artery smooth muscle cells. J Physiol (Lond) 1996; 496(2):407-420.
51. Allbritton NL, Oancea E, Kuhn MA, Meye T. Source of nuclear calcium signals. Proc Natl Acad Sci USA 1994; 91:12458-12462.
52. Mogami H, Kojima I. Stimulation of calcium entry is prerequisite for DNA synthesis induced by platelet-derived growth factor in vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 196(2):650-658.
53. Chao T-S, Byron KL, Lee KM, Villereal M, Rosner MR. Activation of MAP kinases by calcium-dependent and calcium-independent pathways: stimulation by thapsigargin and epidermal growth factor. J Biol Chem 1992; 267(28):19876-19883.
54. 2+ pool content is linked to control of cell growth. Proc Natl Acad Sci USA 1993; 90:4986-4990.
55. Archer SL, Huang JMC, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP- dependent protein kinase. Proc Natl Acad Sci USA 1994; 91:7583-7587.
56. + channels. Proc Natl Acad Sci USA 1996; 93:10489-10494.
57. Yu SP, Yeh C-H, Sens SL, Gwag BJ, Canzoniero LMT, Farhangrazi ZS, Ying HS, Tian M, Dugan LL, Choi DW. Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 1997; 278:114-17.
58. + channels. In:Lopez-Barnes J, Weir EK, eds. Oxygen Regulation of Ion Channels and Gene Expression. New York: Futura, 1998:207-233.
59. Murray TR, Chen L, Marshall BE, Macarak EJ. Hypoxic contraction of cultured pulmonary vascular smooth muscle cells. Am J Respir Cell Mol Biol 1990; 3:457-465.
60. McMurtry IF, Davidson AB, Reeves JT, Grover RF. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res 1976; 38:99-104.
61. 2+-dependent action potentials in small pulmonary arteries of the cat. J Appl Physiol 1985; 59:1389-1393.
62. Madden JA, Dawson CA, Harder DR. Hypoxia-induced activation in small isolated pulmonary arteries from the cat. J Appl Physiol 1985; 59:113-119.
63. Yuan X-J, Goldman WF, Tod ML, Rubin LJ, Blaustein MP. Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol 1993; 264:L116-L123.
64. Post JM, Hume JR, Archer SL, Weir EK. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992; 262:C882-C890.
65. Archer SL, Huang J, Henry T, Peterson D, Weir EK. A redox-based O2 sensor in rat pulmonary vasculature. Circ Res 1993; 73:1100-1112.
66. + channel in oxygen-sensitive pulmonary artery myocytes. EMBO J 1997; 16:6615-6625.
67. Salvaterra CG, Goldman WF. Acute hypoxia increases cytosolic calcium in cultured pulmonary arterial myocytes. Am J Physiol 1993; 264:L323-L328.
68. 2+ in pulmonary and cerebral arterial myocytes. Am J Physiol 1993; 265:L591-L597.
69. + channel β subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997; 100:2347-2353.
70. + currents in pulmonary arterial myocytes. Am J Physiol 1999; 277:L431-L439.
71. + current in rat pulmonary artery muscle cells. Am J Physiol 1994; 266:H365-H370.
72. + channels. J Physiol 1995; 483:115P-116P.
73. Evans AM, Clapp LH, Gurney AM. Augmentation by intracellular ATP of the delayed rectifier current independently of the glibenclamide-sensitive K-current in rabbit arterial myocytes. Br J Pharmacol. 1994; 111(4):972-974.
74. 2+ conductances in pulmonary artery cells. Am J Physiol 1994; 267:L52-L63.
75. Yuan X-J, Sugiyama T, Goldman WF, Rubin LJ, Blaustein MP. A mitochondrial uncoupler increases KCa currents but decreases KV currents in pulmonary artery myocytes. Am J Physiol 1996; 270:C321-C331.
76. + channels. Annu Rev Physiol 1997; 59:23-43.
77. Marshall C, Mamary AJ, Verhoeven AJ, Marshall BE. Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol 1996; 15(5):633-644.
78. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95(20):11715-11720.
79. Waypa GB, Chandel NS, Kulisz A, Schumacker PT. Mitochondrial reactive oxygen species are involved in hypoxic pulmonary vasoconstriction (HPV). Am J Respir Crit Care Med 1999; 159(3):A569.
80. + currents in pulmonary arterial myocytes. Am J Physiol 1995; 268:C259-C270.
81. Campbell WB, Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 1999; 84(4):484-488.
82. Lombard JH, Kunert MP, Roman RJ, Falck JR, Harder DR, Jackson WF. Cytochrome P-450 omega-hydroxylase senses O2 in hamster muscle, but not cheek pouch epithelium, microcirculation. Am J Physiol 1999; 276:H503-H508.
83. Fanburg BL, Massaro DJ, Cerutti PA, Gail DB, Berberich MA. Regulation of gene expression by O2 tension. Am J Physiol 1992; 262:L235-L241.
84. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76:839-885.
85. + current in rat intrapulmonary arterial myocytes by endothelin-1. Am J Physiol 1998; 274:L842-L853.
86. + channel gene transcription in primary pulmonary hypertension. Lancet 1998; 351(9104):726-727.
87. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98:1400-1406.
88. + current in cultured adult human atrial myocytes. Circ Res 1997; 80:572-579.
89. 2+ entry in human arterial myocytes. Am J Physiol 1999; 277:C343-C349.
90. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, Siemieniak DR, Wheeler L, Phillips JA III, Newman JH, Conneally PM, Ginsburg D, Loyd JE. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nature Genet 1997; 15:277-280.
91. + channels in human pulmonary-artery smooth-muscle cells. Lancet 1998; 352(9124):290.
92. Weir EK, Reeve HL, Huang JMC, Michelakis E, Nelson DP, Hampl V, Archer SL. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 93:2216-2220.
93. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173-1174.
94. Orekhov AN, Tertov VV, Smirnov VN. Prostacyclin analogues as antiatherosclerotic drugs. Lancet 1983; 2:521.
95. Yuan X-J, Bright RT, Aldinger AM, Rubin LJ. Nitric oxide inhibits serotonin-induced calcium release in pulmonary artery smooth muscle cells. 1997; Am J Physiol 1997; 272:L44-L50.
96. Kannan MS, Prakash YS, Sieck GC. Nitric oxide inhibits calcium release from sarcoplasmic reticulum of porcine tracheal smooth muscle cells. Am J Physiol 1997; 272:L1-L7.
97. 2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res 1988; 62:961-964.